R
Robert A. Fenstermaker
Researcher at Roswell Park Cancer Institute
Publications - 134
Citations - 4623
Robert A. Fenstermaker is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Glioma & Survivin. The author has an hindex of 38, co-authored 125 publications receiving 4217 citations. Previous affiliations of Robert A. Fenstermaker include University at Buffalo & University Hospitals of Cleveland.
Papers
More filters
Journal ArticleDOI
Central nervous system cancers: Clinical Practice Guidelines in Oncology.
Steven Brem,Philip J. Bierman,Peter M. Black,Deborah T. Blumenthal,Henry Brem,Marc C. Chamberlain,Ennio Antonio Chiocca,Lisa M. DeAngelis,Robert A. Fenstermaker,Howard A. Fine,Allan H. Friedman,Jon Glass,Stuart A. Grossman,Amy B. Heimberger,Larry Junck,Victor A. Levin,Jay J. Loeffler,Moshe H. Maor,Ashwatha Narayana,Herbert B. Newton,Alessandro Olivi,Jana Portnow,Michael D. Prados,Jeffrey Raizer,Steven S. Rosenfeld,Dennis C. Shrieve,Allen K. Sills,Alexander M. Spence,Frank D. Vrionis +28 more
TL;DR: These guidelines provide recommendations on the diagnosis and management of this group of diseases based on clinical evidence and panel consensus and include expert advice on the management of low-grade infiltrative astrocytomas, oligodendrogliomas, anaplastic gliomas, glioblastomas, medulloblastoma, supratentorial primitive neuroectodermal tumors, and brain metastases.
Journal ArticleDOI
Central Nervous System Cancers
Louis B. Nabors,Mario Ammirati,Philip J. Bierman,Henry Brem,Nicholas Butowski,Marc C. Chamberlain,Lisa M. DeAngelis,Robert A. Fenstermaker,Allan H. Friedman,Mark R. Gilbert,Deneen Hesser,Matthias Holdhoff,Larry Junck,Ronald Lawson,Jay S. Loeffler,Moshe H. Maor,Paul L. Moots,Tara Morrison,Maciej M. Mrugala,Herbert B. Newton,Jana Portnow,Jeffrey J. Raizer,Lawrence Recht,Dennis C. Shrieve,Allen K. Sills,David Tran,Nam D. Tran,Frank D. Vrionis,Patrick Y. Wen,Maria Ho +29 more
TL;DR: These guidelines provide recommendations on the diagnosis and management of this group of diseases based on clinical evidence and panel consensus and include expert advice on the management of low-grade infiltrative astrocytomas, oligodendrogliomas, anaplastic gliomas, glioblastomas, medulloblastoma, supratentorial primitive neuroectodermal tumors, and brain metastases.
Journal ArticleDOI
Acting via a Cell Surface Receptor, Thyroid Hormone Is a Growth Factor for Glioma Cells
Faith B. Davis,Heng-Yuan Tang,Ai Shih,Travis Keating,Lawrence Lansing,Aleck Hercbergs,Robert A. Fenstermaker,Ahmed S. Mousa,Shaker A. Mousa,Paul J. Davis,Paul J. Davis,Hung Yun Lin +11 more
TL;DR: The present experiments infer a novel cell membrane receptor-mediated basis for the growth-promoting activity of thyroid hormone in such tumors and suggest new therapeutic approaches to the treatment of patients with glioblastoma.
Journal ArticleDOI
Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy
Gong Wu,Rolf F. Barth,Weilian Yang,Madhumita Chatterjee,Werner Tjarks,Michael J. Ciesielski,Robert A. Fenstermaker +6 more
TL;DR: The purpose of the present study was to investigate the use of the chimeric MoAb cetuximab (IMC-C225), which is directed against EGFR and EGFRvIII, as a boron delivery agent for neutron capture therapy (NCT) of brain tumors.
Journal ArticleDOI
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
Li Shen,Michael J. Ciesielski,Swathi Ramakrishnan,Kiersten Marie Miles,Leigh Ellis,Paula Sotomayor,Protul Shrikant,Robert A. Fenstermaker,Roberto Pili +8 more
TL;DR: The Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer model is reported, demonstrating a novel immunomodulatory effect of class I HDAC inhibition.